Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Atara Biotherapeutics, Inc. securities during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and regulatory prospects [1][5]. Group 1: Class Action Details - The class action lawsuit pertains to securities purchased between May 20, 2024, and January 9, 2026, and aims to address alleged misleading statements made by Atara Biotherapeutics [1]. - Investors who purchased Atara securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly, with a deadline for lead plaintiff applications set for May 22, 2026 [3][6]. Group 2: Allegations Against Atara Biotherapeutics - The lawsuit claims that Atara Biotherapeutics made false and misleading statements regarding manufacturing issues and regulatory prospects related to the tabelecleucel Biologics License Application [5]. - Specific allegations include that manufacturing deficiencies and issues with the ALLELE study made FDA approval unlikely, overstating the regulatory prospects of tabelecleucel [5]. - The lawsuit asserts that these misrepresentations likely had a significant negative impact on Atara's business and financial condition, leading to investor damages when the truth was revealed [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked highly for settlements since 2013 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, showcasing its capability in handling such cases [4].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Atara Biotherapeutics, Inc. ("Atara†or the "Company†) (NASDAQ: ATRA) investors concerning the Company's possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON ATARA BIOTHERAPEUTICS, INC. (ATRA), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Wh. ...

Core Viewpoint - A class action lawsuit has been filed against Atara Biotherapeutics, Inc. for alleged violations of federal securities laws during the class period from May 20, 2024, to January 9, 2026 [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover damages for investors who purchased Atara securities during the specified class period [2]. - The complaint alleges that defendants made false or misleading statements regarding manufacturing issues and regulatory prospects related to the tabelecleucel BLA [3]. - Specific allegations include that manufacturing issues and deficiencies in the ALLELE study made FDA approval unlikely, overstated regulatory prospects, increased risk of regulatory scrutiny, and negatively impacted Atara's business and financial condition [3]. Group 2: Next Steps for Investors - Investors wishing to join the lawsuit must request to be appointed as lead plaintiff by May 22, 2026, although participation in any recovery does not require serving as lead plaintiff [4]. - A copy of the complaint can be reviewed on the law firm's website [4]. Group 3: Legal Representation - Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, meaning they will only seek reimbursement for expenses and fees if successful [5]. - The firm has a strong track record, having recovered hundreds of millions of dollars for investors in securities fraud class actions [6].

Core Viewpoint - Atara Biotherapeutics, Inc. is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its product tabelecleucel and associated manufacturing issues [4]. Group 1: Lawsuit Details - The Schall Law Firm is leading a class action lawsuit against Atara Biotherapeutics for violations of the Securities Exchange Act of 1934 [1]. - Investors who purchased Atara's securities between May 20, 2024, and January 9, 2026, are encouraged to participate in the lawsuit before May 22, 2026 [2]. - The lawsuit claims that Atara made false statements about its manufacturing capabilities and the likelihood of FDA approval for tabelecleucel, leading to investor losses when the truth was revealed [4]. Group 2: Company Issues - Atara is reported to have faced significant manufacturing problems and deficiencies in its ALLELE study, which raised concerns about regulatory approval [4]. - The company allegedly overstated the prospects of its product tabelecleucel, which contributed to the misleading public statements [4]. - The lawsuit indicates that Atara's public statements were materially misleading throughout the class period, resulting in damages to investors when the actual situation became known [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Atara Biotherapeutics, Inc. securities, alleging misleading statements and undisclosed manufacturing issues that affected the company's regulatory prospects and financial condition during the Class Period from May 20, 2024, to January 9, 2026 [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Atara Biotherapeutics made false and misleading statements regarding manufacturing issues and the likelihood of FDA approval for its tabelecleucel Biologics License Application [5]. - The lawsuit alleges that these issues led to a heightened risk of regulatory scrutiny and jeopardized ongoing clinical trials, which negatively impacted Atara's business and financial condition [5]. - Investors are encouraged to join the class action to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in securities class action services [4]. - Investors can join the class action by submitting a form or contacting the firm directly for more information [3][6].

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Atara Biotherapeutics, Inc. for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Investigation Details - The investigation pertains to disclosures made by Atara on January 16, 2025, regarding its operations and financial status [1]

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Atara Biotherapeutics, Inc. securities during the specified Class Period, indicating potential legal issues for the company related to misleading statements and regulatory challenges [1][5]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Atara securities between May 20, 2024, and January 9, 2026 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been recognized for its performance in securities class action settlements [4]. Group 3: Allegations Against Atara - The lawsuit alleges that Atara made false or misleading statements regarding manufacturing issues and regulatory prospects for its tabelecleucel Biologics License Application [5]. - It is claimed that these issues heightened regulatory scrutiny and jeopardized ongoing clinical trials, negatively impacting Atara's business and financial condition [5].

Core Viewpoint - A securities class action lawsuit has been filed against Atara Biotherapeutics, alleging that the company failed to disclose significant manufacturing issues and deficiencies in its clinical study, which could negatively impact its regulatory approval and financial condition [1][2]. Group 1: Lawsuit Details - The lawsuit is filed in the United States District Court for the Central District of California on behalf of individuals or entities that purchased Atara securities between May 20, 2024, and January 9, 2026 [1]. - The complaint claims that Atara's public statements were materially false and misleading due to undisclosed manufacturing issues and regulatory risks associated with its product tabelecleucel [2]. Group 2: Investor Information - Investors who acquired shares of Atara are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on May 22, 2026 [3]. - The firm provides contact information for interested investors to discuss their rights or interests regarding the class action [3].

LOS ANGELES, March 25, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Atara Biotherapeutics, Inc., (“Atara” or the "Company") (NASDAQ: ATRA) investors of a class action on behalf of investors that bought securities between May 20, 2024 and January 9, 2026, inclusive (the “Class Period”). Atara investors have until May 22, 2026 to file a lead plaintiff motion. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal r ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Atara Biotherapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and undisclosed manufacturing issues affecting the company's product approval process [2][5]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Atara between May 20, 2024, and January 9, 2026, to discuss their legal options [1]. - A federal securities class action has been filed against Atara, with a deadline of May 22, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Atara and its executives made false statements regarding the regulatory prospects of the tabelecleucel BLA, which were overstated due to manufacturing issues [5]. Group 2: Impact of FDA Response - On January 12, 2026, Atara announced that the FDA issued a Complete Response Letter for the EBVALLO™ BLA, indicating that the application could not be approved in its current form due to inadequacies in the ALLELE trial [6]. - Following the FDA's announcement, Atara's stock price fell by $7.79 per share, or 56.99%, closing at $5.88 per share [6]. Group 3: Company Background - Faruqi & Faruqi, LLP is a national securities law firm with a history of recovering hundreds of millions of dollars for investors since its founding in 1995 [4].